Diabetes

CV Outcomes in Diabetes

Risk reduction with antihyperglycaemic therapies

 

Cardiovascular (CV) disease remains the leading cause of morbidity and mortality in patients with type 2 diabetes (T2D).

 

The opportunity for CV disease prevention in patients with T2D has recently expanded with antihyperglycaemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE). Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.

 

CV specialists are well-positioned to play a key role in managing patients with T2D, including screening, aggressively treating CV risk factors, and incorporating the use of antihyperglycaemic agents into routine practice.

Close X
Other videos you might like

Section Advisor

Professor Mikhail N Kosiborod

Saint Luke's America Heart Institute, Kansas City, MO, US

The Radcliffe diabetes and CVD risk program is supported by an educational grant from Novo Nordisk.

Recent Videos

Video

SPLENDOR: Metabolic Surgery and Risk of MACE in NASH
Ali Aminian

Video

RESPONSE-2: Long Term Outcomes of Lifestyle Programme in CAD Patients
Harald Thune Jorstad

Video

ESC 2021 Discussion: The FIGARO-DKD Trial
Bertram Pitt, Harriette Van Spall

Video

ESC 2021 Discussion: The EMPEROR-Preserved Trial
Stefan Anker, Harriette Van Spall

Video Series

SGLT2i Updates 2021
Stefan Anker, Shelley Zieroth, Andrew JS Coats

Video

ACC 21: Benefits of SGLT1/2 Inhibition Across the Full Spectrum of EF
Deepak L Bhatt, Harriette Van Spall
Everything in Moderation: Investigating the U-Shaped Link Between HDL Cholesterol and Adverse Outcomes

US Cardiology Review 2019;13(1):49–53

Diabetic Cardiomyopathy: Five Major Questions with Simple Answers

US Cardiology Review 2019;13(1):46–8

Diabetes Drugs and Cardiovascular Event Reduction: A Paradigm Shift

US Cardiology Review 2018;12(1):46–50.

Novel Pharmacologic Treatments for Cardiovascular Disease: A Practical Update

US Cardiology Review 2017;11(2):98–104.

Identification of Patients at Risk of Stroke From Atrial Fibrillation

US Cardiology Review 2016;10(2):60–4

What the Cardiologist Needs to Know About Medications for Type 2 Diabetes

US Cardiology Review 2016;10(2):54–9

Foreword

US Cardiology, 2006;3(1):11

Detection of Silent Coronary Artery Disease in Asymptomatic Patients with Type 2 Diabetes Mellitus

US Cardiology 2005;2(1):44–6

Cardiovascular Risk Factors in Metabolic Syndrome—Impact of Insulin Resistance on Lipids, Hypertension, and the Development of Diabetes and Cardiac Events

US Cardiology 2005;2(1):35–8

The Cardiologist's Role in the Management of Type 2 Diabetes - A Review

US Cardiology 2012;9(1):26-9

Treatment of Type 2 Diabetes with a Combination of Two Insulin Sensitizers — Increased Efficacy and Fewer Side-effects

US Cardiology 2004;1(1):29–33

High-density Lipoprotein Cholesterol — The Next Battle Front in the Fight Against Heart Disease

US Cardiology 2004;1(1):34–8

Angiotensin-receptor Blocker Therapy—Chronic Kidney Disease and Diabetes

US Cardiology 2006;3(2):32–4

Treating the Common Dyslipidemia in Patients with Type 2 Diabetes—The Effects of Fenofibrate on Cardiovascular Disease Risk

US Cardiology 2006;3(1):1–5

Management of Cholesterol in Diabetes - A Review

US Cardiology 2010;7(2):20–4

Management of the Asymptomatic Diabetic Patient with Evidence of Ischemia

US Cardiology 2010; 7(1):76–80

Cardiovascular Risk in Type 2 Diabetes - Reflecting on the ADVANCE Study

US Cardiology 2009;6(2):46–50

Minimizing Cardiovascular Complications by Early Diagnosis of Diabetes

US Cardiology 2007;4(1):35–6

Metabolic Syndrome - A Common and Dangerous Health Problem

US Cardiology 2007;4(1):37–40

Hypertension and Diabetes Mellitus

US Cardiology 2005;2(1):1–7